PD166326（Cat No.:I008617）is a potent, ATP-competitive inhibitor of Bcr-Abl and Src family tyrosine kinases, with strong activity against both wild-type and mutant forms of Bcr-Abl, including the T315I mutation. It exhibits nanomolar IC₅₀ values and effectively blocks aberrant kinase signaling involved in chronic myeloid leukemia (CML) and other malignancies. PD166326 induces apoptosis and inhibits proliferation in Bcr-Abl–positive cells, making it a valuable compound for cancer research. Researchers use it to explore resistance mechanisms, validate kinase targets, and develop next-generation tyrosine kinase inhibitors in oncology.